Dernières nouvelles pour Pharming (NASDAQ:PHAR) Stock

PHARMING GROUP NV - ADR

Pharming

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

News

Press Releases

Pharming Group to participate in February investor conference

Pharming Group to report fourth quarter and full year 2024 financial results on March 13

Pharming Group to participate in March investor conference

Management

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Earnings

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

General

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

PHAR

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

ArriVent BioPharma

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Gyre Therapeutics

Immunome

Immatics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Jyong Biotech

MeiraGTx Hldgs

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Prime Medicine

Replimune Group

Relay Therapeutics

Sage Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Tango Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

Vir Biotechnology

Xencor

HC Wainwright & Co.

Oppenheimer

Jefferies

Comments

Pharming

Actualités

Dernières nouvelles pour Pharming (NASDAQ:PHAR) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL